H ereditary thrombophilia describes an inherited tendency for venous thrombosis (VT). Coagulation inhibitor (protein C [PC], protein S [PS], or antithrombin [AT]) deficiencies are found in <1% of the population and represent only a small percentage of patients with VT. 1 These deficiencies increase the risk of VT ≈10-fold in heterozygous carriers, with the highest risk observed for AT deficiency. 1 Factor V Leiden (FVL) is present in 4% to 6% of the general population, and heterozygosity for this mutation leads to a 3-fold increase in relative risk of VT. F2 20210A is less common (found in 2% of whites) and increases the risk of VT ≈3-fold. 1 These 5 defects follow an autosomal dominant inheritance model. Genetic counseling in families with VT based on the screening for these 5 defects is still debated. Indeed, identifying the defect in asymptomatic family members from a proband with VT would identify those at high risk and therefore allow avoidance of high-risk situations or facilitate targeted prophylaxis at time of unavoidable high risk. However, despite harbouring the same gene mutation, affected individuals even within families frequently exhibit marked clinical heterogeneity. As an example, the penetrance of the FVL is low because only 10% of heterozygotes and 80% of homozygotes develop VT in their lifetime, with varying severity among affected individuals.
These observations strongly support that the individual risk within these families is affected by multiple genetic and environmental factors, which will be different even among first-degree relatives. Thus, identifying these modifying risk factors will allow a more accurate definition of the individual risk and is of major importance from therapeutical perspective. Two genome-wide association studies recently published identified ABO and FVL as the 2 major susceptibility genes for VT. 2, 3 ABO locus, a known susceptibility locus for VT, 4 is located on chromosome 9 (9q34.1-q34.2) and consists of a single gene of which different alleles exist. 5 The A and B alleles encode slightly different glycosyltransferases that add N-acetylgalactosamine and D-galactose, respectively, to a common precursor side chain, the H determinant, converting it into A or B antigens. The O alleles do not encode a functional enzyme. In OO carriers, the H antigen remains unmodified with a fucose moiety attached to precursor oligosaccharide chains. A single base deletion is found in the A gene, which characterizes the A2 allele. As a result of a frameshift, the glycosyltransferase specified by the A2 allele has an additional carboxy-terminal domain, which seems responsible for the drastic reduction in enzyme activity. 6 Non-O blood group carriers share a 1.79% higher risk of VT than O carriers. 7 It is noteworthy that, although the relative risks associated with the ABO blood groups are lower than that associated with the FVL, its population attributable fraction is much higher (30% for the non-O status versus 17% for FVL) 7 . This is attributable to the high prevalence of the non-O blood groups which is estimated to be ≈54% in whites. 8 Moreover, in a population of unrelated individuals, it has been observed that non-O blood group more strongly influences the risk of VT in FVL carriers than in noncarriers. 9 This strong interaction was not observed in another study. 2 The effect of ABO blood group on VT risk is believed to be mediated by an effect on von Willebrand factor (VWF) and factor VIII (FVIII) 10 which plasma levels also influence VT risk. 11 Differences in ABO blood group antigen expression may affect VWF glycosylation, and thus its proteolysis and clearance, 12, 13 which in turn may affect FVIII levels. However, in a prospective study, ABO remained significantly associated with VT risk even after controlling for FVIII levels, 14 suggesting that there may be other factors involved in the association between ABO blood group and VT.
The aim of the present study was to evaluate the risk of VT in a large cohort of 1774 relatives from 500 families with inherited thrombophilia. We analyzed the contribution of VWF, FVIII plasma levels, and ABO blood group to the risk of VT according to the severity of thrombophilia.
Methods

Patients
The cohort included consecutive families from the Marseille area in France which came to the thrombophilia center of La Timone Hospital between September 1986 and December 2008, and identified as follows: probands had at least 1 episode of VT, underwent screening for thrombophilia, and had at least 1 of the inherited defects associated with thrombophilia (AT, PC, PS deficiency, FVL, F2G20210A mutation). We selected only families for which the inheritance of coagulation defect was demonstrated (at least 2 family members, including the proband had to be carriers of the same defect). Families identified before January 2003 were readdressed between April 2003 and December 2004 for completion of thrombophilia screening and collection of plasma and DNA. A total of 1774 relatives from 500 families with inherited thrombophilia were recruited. One thousand, two hundred eight were first-degree relatives, and 566 were second-degree relatives. These 566 subjects were recruited only from families with AT, PC, or PS deficiency to increase the number of subjects studied with these rare defects. We obtained a detailed medical history with special emphasis on previous episodes of VT. In all cases, a history of VT was recorded before the laboratory diagnosis was made. As VT, we referred to any documented episode of deep vein thrombosis (ie, thrombosis affecting the deep veins of the lower and upper extremities, the superior and inferior cava veins, the cerebral veins, and the portalmesenteric circulation) or pulmonary embolism. VT was considered established if deep vein thrombosis was confirmed by compression ultrasound or venography, and pulmonary embolism by ventilation and perfusion lung scanning, spiral computed tomography scanning, or pulmonary angiography, or when the patient had received full-dose heparin and a vitamin K antagonist for at least 3 months. VT was classified as secondary when occurring within 3 months after exposure to exogenous risk factors, including surgery, trauma, immobilization for ≥7 days, oral contraceptive use, pregnancy, puerperium, and during malignancy. In the absence of these risk factors, VT was defined as idiopathic. We obtained informed consent from all patients, and the study met all institutional ethics requirements.
Blood Sample Collection and Preparation
Blood samples were collected by antecubital venipuncture into vacutainer tubes containing 0.105-mol/L −1 trisodium citrate (ratio 9:1; Becton Dickinson, Pont de Claix, France) for the coagulation test.
Biological Tests
All hemostasis-related parameters were centrally performed using the Star automate and commercially available kits and reagents from Diagnostica Stago (Asniéres, France) including the corresponding normal and pathological control plasmas and standard plasmas. Fibrinogen plasma levels were assayed using the STA Fibrinogen kit (Clauss method). AT was measured with the AT chromogenic AT heparin cofactor activity (Stachrom AT III). AT deficiency was defined by decreased levels of AT activity (<80 IU/dL −1 ). 15 PS deficiency was defined by decreased free PS plasma antigen levels using specific ELISA assay (<55 IU/dL −1 ). 16 PC deficiencies were defined by decreased levels of PC activity measured by Staclot PC (<70 IU/ dL −1 ). 15 Because PC and PS are vitamin K-dependant proteins and their plasma levels decrease by the concomitant use of vitamin K antagonists, PC and PS were measured at least 1 month after withdrawal of these drugs. Deficiencies were considered inherited if they were confirmed by measuring a second sample that was collected 3 months later and were found in at least 2 family members. FVIII and VWF levels are respectively measured by VIII:C using human FVIII-deficient plasma in a 1-stage factor assay and by STA LIATEST VWF (Diagnostica Stago) on Star automate. They were measured at least 3 months after the most recent VT event to minimize the effect of the acute phase.
ABO groups were phenotyped with QWALYS 2 automate (Diagast, Loos, France). This allowed the identification of O, A, B, and AB carriers. Mean platelet volume was determined by ADVIA 120 Hematology System (Siemens Healthcare Diagnostics, Deerfield, IL).
Genetic Screening
For the molecular diagnostic testing for FVL, F2G20210A, and ABO genotyping, we used the light cycler technology (Roche Diagnostics, Indianapolis, IN) as previously described. 3 For ABO, we genotyped the single nucleotide polymorphism rs8176719 for allele O1, single nucleotide polymorphism rs1053878 for allele A2, and single nucleotide polymorphism rs8176743 for allele B. If none of these alleles were presented, we considered that the patient group was A1.
Statistical Analysis
Probands were excluded from the analysis to avoid bias. In the present study, we proposed to set up groups depending on the severity of the thrombophilia in accordance with the recommendations. 17, 18 Three groups were thus defined: high-risk thrombophilia, which includes subjects with deficiency of AT, PC, PS, homozygosity for FVL or F2G20210A mutation, and subjects with compound heritable thrombophilia (ie, carrying >1 defect); low-risk thrombophilia includes subjects heterozygous for the FVL or F2G20210A mutation; and no thrombophilia includes all patients without congenital thrombophilic defect.
First, a descriptive analysis was performed. The continuous variables were described using means and SDs, and categorical data were described using percentages with the associated P values. The incidence rate was assessed by dividing the counts of VT by the whole sample size and the sum of the observation time for each individual. The observation time was defined as the period from birth until the first VT episode or the end of the study (the end of the study is defined as the minimum between age at the visit with the clinician or 60 years of age which was our end point). Note that there were no patients lost to follow-up. These incidence rates were assessed according to the type of deficiency, the thrombophilia group, and the ABO group. The incidence rate was presented as percentages (%) and as person-years (100 000 PA). The hazard ratio (HR) was assessed using a univariate Cox model with frailty. The random effect (called frailty in survival analysis) 19 was added to account for the nonrandomness of the relatives analyzed; therefore the outcome rates were also adjusted for clustering within families.
Then a univariate analysis was performed to study the relation between the risk for VT and the clinical and biological covariates in relatives. The univariate analysis was performed to select the covariates which will be introduced in the multivariate analysis. Thus, the univariate analysis consisted of the following: (1) assessing the link between VT and covariates using a univariate frailty Cox model, (2) providing survival graphics for Kaplan-Meier estimates (just for descriptive purpose), and (3) checking for the log-linearity and proportional hazard assumptions. For continuous variables when the log-linearity assumption was true, a univariate frailty Cox model was performed including the covariate as a continuous variable. When the assumption was not true, such as for VWF and FVIII levels, continuous data were categorized according to deciles (and categories with a similar risk were pooled), or clinical thresholds were used. The proportional hazards were tested, and the interaction with time was considered when the assumption was not true.
All variables potentially linked to VT (significance level of P<0. 20) were introduced in a multivariate analysis. The variables were as follows: sex, severity of thrombophilia, ABO type, FVIII, VWF, and mean platelet volume. A frailty Cox model was proposed as a multivariate analysis to select determinants of VT and to assess the HR. A backward step-by-step procedure was used to select significant covariates. All variables that were not significant at a P value threshold of 5% were excluded from the model. The final model selected only significant variables and assessed the associated HR.
All analyses were performed with R Software version 2.12.1 (http://cran.r-project.org/; R Development Core Team [2012], R Foundation for Statistical Computing, Vienna, Austria).
Results
Clinical Characteristics
The cohort consisted of 500 unrelated families from 18 (3.6%) AT-deficient probands, 66 (13.2%) PC-deficient, 40 (8%) PS-deficient, and 300 (60%) individuals with FVL, 137 with F2G20210A mutation (main characteristics of probands are presented in Table I in the online-only Data Supplement). A flow chart of the study is presented in Figure 1 , and main clinical characteristics of the 1774 relatives are presented in Table 1 . Briefly, individuals with VT were older than those without VT and had a higher body mass index. High-risk thrombophilia was most frequent in individuals with VT compared with those without VT. O group carriers were less frequent in individuals with VT compared with those without VT. Table 2 ). In individuals with FVL and F2G20210A, annual incidences were 0.31% and 0.25%, respectively with corresponding HRs of 1.99 (1.3-3.1) and 1.6 (0.9-2.9). Annual incidence for combined defects was 0.66% (HR=4.6 [2.4-8.7] ).
Annual Incidence and HR of VT According to the Severity of Thrombophilia
Three different risk groups were formed according to the severity of thrombophilia: no, low-(FVL or F2G20210A heterozygous carriers), and high-risk thrombophilia (AT, PC, PS deficiency, FVL, or F2G20210A homozygous carriers and combined defects). The annual incidence was 0.53% (HR=3.7 [2.4-5.7]) and 0.29% (HR=1.9 [1.2-2.8]) in high-and lowrisk thrombophilia group, respectively compared with the group without any defect. Figure 2A shows the event-free survival of VT in relatives according to the severity of thrombophilia. The event-free likelihood before 60 years of age in relatives in the high-risk group was 0.73 (versus 0.78 and 0.90 in the low-risk and no thrombophilia, respectively). The survival was therefore significantly better in the no thrombophilia group (log-rank test P<0.0001).
Effect of ABO, VWF, and FVIII Levels on the Risk of VT
When the phenotypic ABO blood groups were considered, the AB group was associated with an increased risk (Table 3 and Figure 3A ). The effect of blood group A and B was milder (HR=1.6 [1.1-2.5] and 1.8 [1.0-3.3], respectively). The event-free survival likelihood in relatives with the AB blood group ( Figure 2B ) was 0.764 compared with 0.794, 0.867, 0.877 for A, B, and O groups, respectively. The survival was therefore significantly different according to the blood group (log-rank test P<0.0001) and worse in AB carriers (P<0.0001 and 0.0123 for comparison with O and AB groups, respectively).
When the ABO genotyping was considered, A1B and A2B group carriers had similar risk of VT ( Figure 3B ) and presented the highest levels of VWF and FVIII. The lowest risk of VT was observed in A2A2 and OO individuals. Carrying 0 or 1 copy of O or A2 led to similar risk of VT despite higher levels of VWF and FVIII in those with 0 copy (HR=0.54 [0.34-0.86] for 1 versus 0 and HR=0.37 [0.22-0.60] for 2 versus 0; Figure 3C ).
An increased risk of VT was observed with increasing plasma levels of VWF and FVIII (Table II in the online-only  Data Supplement) . For VWF, HRs for second versus first tertile and third versus first tertile were 1.57 (1.05-2.36) and 2.96 (1.92-4.56), respectively. Corresponding HRs were 1.53 (1.00-2.33) and 2.60 (1.62-4.17), respectively for FVIII. Event-free survival of VT in relatives was significantly different according to VWF and FVIII levels ( Figure 2C and 2D 
Discussion
ABO blood group is associated with an increased risk of VT in families with hereditary thrombophila. AB blood group carriers presented the highest risk of VT. In individuals with AB blood group and high-risk thrombophilia, the risk increases 14-fold compared with individuals with O blood group and no thrombophilia.
In this large French cohort, we first aimed to study the association with the severity of thrombophilia and the risk of VT. Overall, incidence of VT in individuals with thrombophilia was lower than that reported in the literature from cohorts of families with thrombophilia. [20] [21] [22] [23] [24] [25] [26] [27] However, as expected, AT deficiency was associated with the highest annual incidence of VT (0.79%) and F2G20210A with the lowest (0.25%). In individuals with no thrombophilia, the annual incidence of VT was 0.17%, which is higher than that observed in the general population as previously reported. [20] [21] [22] [23] [24] [25] [26] [27] This higher incidence of VT is likely attributable to other genetic risk factors which cosegregate within these families. We tested the impact of ABO blood group, a well-known genetic risk factor for VT, on our families with thrombophilia. Non-O blood groups were associated with an increased risk of VT, though the risk was not homogeneous among them. Indeed, the highest risk being observed in AB carriers who have a 4-fold risk compared with O carriers. A and B carriers have intermediate and similar risks (1.6 and 1.8 compared with O group, respectively). This is in line with the fact that among the non-O group, AB individuals have the highest VWF levels as previously reported 28 (Table III in Quantitative values are means (SD), and qualitative values are n (%). VT+ is the personal history of VT. High-risk thrombophilia is the deficiency of antithrombin, protein C, protein S, patients homozygous for factor V Leiden and F2G20210A mutation, and subjects with compound heritable thrombophilia.
Low-risk thrombophilia is heterozygous for the factor V Leiden or F2G20210A mutation.
No thrombophilia is patients without congenital thrombophilic defect.
Supplement). We tested whether genotyping of ABO would lead to a more accurate risk assessment than phenotyping. The idea was that this genotyping will allow to separate A and B blood group carriers with 2 copies (ie AA and BB) or 1 copy (ie, AO and BO), these latter being associated with intermediate values of VWF and FVIII levels. 10 This also allows to identify A1 and A2 carriers; the latter carries a partly unfunctional glycosyltransferase 6 and are associated with lower VWF and FVIII 29 and a lower risk of VT. 3 Surprisingly, A1B and A2B carriers displayed the same VT risk though the number of A2B carriers was rather small. A1B and A2B had a higher risk of VT than A and B carriers, where the risk of VT was similar in those carrying 2 (ie, AA or BB) or only 1 copy (ie, AO or BO), which is in line with that observed in Wu 7 meta-analysis. Thus, phenotyping of ABO blood group is an easy way to assess the risk mediated by ABO locus and gives enough information by particularly identifying AB carriers who present the highest risk of VT. AT indicates antithrombin; FIIL, F2 20210A; FVL, factor V Leiden; HR, hazard ratio; PC, protein C; PS, protein S; VT, venous thrombosis. When combining ABO blood groups and the severity of thrombophilia, a supraadditive effect was observed, such as individuals with both high-risk thrombophilia and AB groups had a 14-fold increased risk of VT compared with those with no thrombophilia and O blood group. By contrast, in carriers with a low-risk thrombophilia (ie, FVL or F2G20210A heterozygous carriers), those carrying the O blood group were not at increased risk of VT in comparison with individuals without thrombophilia.
ABO blood group is believed to play a role in VT through modifications of VWF and FVIII levels in plasma. As expected, we observed an association between ABO blood groups and VWF and FVIII levels in plasma ( Figure 2 ; Table III in the online-only Data Supplement), these 2 being associated with the risk of VT with a trend toward an increased risk of VT according to increasing plasma levels of both molecules. However, in multivariate analysis, both high levels of VWF (ie, >178 IU/dL) and AB blood groups remained associated with an increased risk of VT. This confirms the results of the Atherosclerosis Risk in Communities Study, where ABO blood group remained significantly associated with VT even after adjustment for FVIII. 14 This suggests that ABO may affect cardiovascular risk by other means than modifications of FVIII and VWF levels and that measuring these factors in plasma does not reflect the overall impact of ABO on VT. Several biological arguments are in favor of a VWF-independent effect of ABO blood group. First, although traditionally regarded as red blood cells antigen, ABO antigens are also expressed on various other tissues including platelets, vascular endothelium, and epithelial surfaces. 12 Second, it has been shown that ABO may also influence activated PC resistance. 30 Last, recently, it has been shown that ABO was associated with soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin plama levels. 31 Further studies are needed to investigate whether the association between variants at the ABO locus and VT is related to changes in these biological phenotypes and, if so, by what mechanisms.
Some methodological aspects of our study warrant comment. First, events were not always confirmed by objective techniques, because these techniques were not available at the time of the event. Therefore, incidences of VT may have been overestimated. Because these were compared with incidences from population studies that used the same classification of VT, [19] [20] [21] relative risk estimates would not change. Moreover, we assume that misclassification of VT would occur equally in relatives with a thrombophilic defect, and those without a thrombophilic defect, and therefore would not change our relative risk estimates. Second, the incidence of VT in individuals with thrombophilia is somewhat lower than in other studies. There are several reasons to explain this observation. Most of them lie in the specific design of each study. Indeed, among the studies aiming to study the risk of VT in relatives of symptomatic probands, 21-26 only 2 have concomitantly studied the effect of the 5 defects. 22, 26 In the study by Tirado et al, 22 the propositi were included, and this can lead to an overestimation of risk. In the study by Lijfering et al, 26 propositi were excluded as in our study. However, several methodological differences remained. The Dutch study 26 has included probands with history of either VT or arterial thrombosis, whereas our study only included probands with history of VT. Moreover, in the study by Lijfering et al, 26 the observation period starts from 15 years of age, whereas our observation period starts from birth. Third, second degree of families with inhibitor deficiency has been included to increase the power of the study (as in the Dutch study for AT deficiency). 26 However, hypothetically, second-degree relatives may have lower baseline risk of VT because the influence of other predispositions (ie, unidentified disorders) would be diluted.
In conclusion, ABO blood group modifies the risk of VT in families with hereditary thrombophilia. Phenotyping of the ABO blood group should be performed to better assess the risk of VT in asymptomatic individuals from thrombophilic families. Figure 3 . Relative risks of venous thrombosis (VT), von Willebrand factor (VWF) and factor VIII (FVIII) plasma levels according to ABO blood groups: A, phenotypic ABO blood groups; B and C, genotypic ABO blood groups. HR indicates hazard ratio.
